The role of second-generation 5-HT 3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies

Lee S. Schwartzberg, Peter Jacobs, Panagiota Matsouka, Wellington Azevedo, Antonio Pinto

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Compared with solid tumor patients, those with hematological malignancies are at particular risk of chemotherapy-induced nausea and vomiting (CINV) because of their young age, exposure to highly-emetogenic induction, consolidation and salvage regimens, the high-dose conditioning regimens used before stem cell transplantation (SCT), and the heavy psychological burden of such treatments. In the absence of prophylaxis, around 75% of patients undergoing SCT experience delayed CINV. With first-generation 5-HT 3 receptor antagonists, only about 20% are completely protected from nausea and vomiting, and this frequent and debilitating adverse event has not been fully addressed. In contrast to solid tumors, there are no internationally agreed guidelines for the prevention and treatment of CINV in hematological malignancies. Work on a consensus is urgently required. The second-generation 5-HT 3 antagonist palonosetron is highly effective in preventing CINV in patients with solid tumors. The extended half-life of this agent and its mechanisms of action including allosteric binding, positive cooperativity and 5-HT 3 receptor internalization, may make it particularly effective in controlling delayed CINV. Although controlled comparisons against first-generation 5HT 3 agents have not yet been conducted in the setting of SCT, available evidence suggests that palonosetron may prove beneficial in preventing CINV in high risk patients with hematological malignancies.

Original languageEnglish (US)
Pages (from-to)59-70
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Volume83
Issue number1
DOIs
StatePublished - Jul 1 2012

Fingerprint

Serotonin Receptors
Hematologic Neoplasms
Nausea
Vomiting
Drug Therapy
Stem Cell Transplantation
Neoplasms
Serotonin Antagonists
Half-Life
Guidelines
Psychology
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

The role of second-generation 5-HT 3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies. / Schwartzberg, Lee S.; Jacobs, Peter; Matsouka, Panagiota; Azevedo, Wellington; Pinto, Antonio.

In: Critical Reviews in Oncology/Hematology, Vol. 83, No. 1, 01.07.2012, p. 59-70.

Research output: Contribution to journalReview article

@article{c5566fde804344ad8fb27daccfc5ce32,
title = "The role of second-generation 5-HT 3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies",
abstract = "Compared with solid tumor patients, those with hematological malignancies are at particular risk of chemotherapy-induced nausea and vomiting (CINV) because of their young age, exposure to highly-emetogenic induction, consolidation and salvage regimens, the high-dose conditioning regimens used before stem cell transplantation (SCT), and the heavy psychological burden of such treatments. In the absence of prophylaxis, around 75{\%} of patients undergoing SCT experience delayed CINV. With first-generation 5-HT 3 receptor antagonists, only about 20{\%} are completely protected from nausea and vomiting, and this frequent and debilitating adverse event has not been fully addressed. In contrast to solid tumors, there are no internationally agreed guidelines for the prevention and treatment of CINV in hematological malignancies. Work on a consensus is urgently required. The second-generation 5-HT 3 antagonist palonosetron is highly effective in preventing CINV in patients with solid tumors. The extended half-life of this agent and its mechanisms of action including allosteric binding, positive cooperativity and 5-HT 3 receptor internalization, may make it particularly effective in controlling delayed CINV. Although controlled comparisons against first-generation 5HT 3 agents have not yet been conducted in the setting of SCT, available evidence suggests that palonosetron may prove beneficial in preventing CINV in high risk patients with hematological malignancies.",
author = "Schwartzberg, {Lee S.} and Peter Jacobs and Panagiota Matsouka and Wellington Azevedo and Antonio Pinto",
year = "2012",
month = "7",
day = "1",
doi = "10.1016/j.critrevonc.2011.09.005",
language = "English (US)",
volume = "83",
pages = "59--70",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - The role of second-generation 5-HT 3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies

AU - Schwartzberg, Lee S.

AU - Jacobs, Peter

AU - Matsouka, Panagiota

AU - Azevedo, Wellington

AU - Pinto, Antonio

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Compared with solid tumor patients, those with hematological malignancies are at particular risk of chemotherapy-induced nausea and vomiting (CINV) because of their young age, exposure to highly-emetogenic induction, consolidation and salvage regimens, the high-dose conditioning regimens used before stem cell transplantation (SCT), and the heavy psychological burden of such treatments. In the absence of prophylaxis, around 75% of patients undergoing SCT experience delayed CINV. With first-generation 5-HT 3 receptor antagonists, only about 20% are completely protected from nausea and vomiting, and this frequent and debilitating adverse event has not been fully addressed. In contrast to solid tumors, there are no internationally agreed guidelines for the prevention and treatment of CINV in hematological malignancies. Work on a consensus is urgently required. The second-generation 5-HT 3 antagonist palonosetron is highly effective in preventing CINV in patients with solid tumors. The extended half-life of this agent and its mechanisms of action including allosteric binding, positive cooperativity and 5-HT 3 receptor internalization, may make it particularly effective in controlling delayed CINV. Although controlled comparisons against first-generation 5HT 3 agents have not yet been conducted in the setting of SCT, available evidence suggests that palonosetron may prove beneficial in preventing CINV in high risk patients with hematological malignancies.

AB - Compared with solid tumor patients, those with hematological malignancies are at particular risk of chemotherapy-induced nausea and vomiting (CINV) because of their young age, exposure to highly-emetogenic induction, consolidation and salvage regimens, the high-dose conditioning regimens used before stem cell transplantation (SCT), and the heavy psychological burden of such treatments. In the absence of prophylaxis, around 75% of patients undergoing SCT experience delayed CINV. With first-generation 5-HT 3 receptor antagonists, only about 20% are completely protected from nausea and vomiting, and this frequent and debilitating adverse event has not been fully addressed. In contrast to solid tumors, there are no internationally agreed guidelines for the prevention and treatment of CINV in hematological malignancies. Work on a consensus is urgently required. The second-generation 5-HT 3 antagonist palonosetron is highly effective in preventing CINV in patients with solid tumors. The extended half-life of this agent and its mechanisms of action including allosteric binding, positive cooperativity and 5-HT 3 receptor internalization, may make it particularly effective in controlling delayed CINV. Although controlled comparisons against first-generation 5HT 3 agents have not yet been conducted in the setting of SCT, available evidence suggests that palonosetron may prove beneficial in preventing CINV in high risk patients with hematological malignancies.

UR - http://www.scopus.com/inward/record.url?scp=84862128456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862128456&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2011.09.005

DO - 10.1016/j.critrevonc.2011.09.005

M3 - Review article

C2 - 22321726

AN - SCOPUS:84862128456

VL - 83

SP - 59

EP - 70

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -